NMC Royal Hospital, 16th Street, Khalifa City, Abu Dhabi, United Arab Emirates; Medical Research Division, Department of Internal Medicine, The National Research Centre, 33 El Buhouth St, Ad Doqi, Dokki, Cairo Governorate 12622, Egypt.
NMC Royal Hospital, 16th Street, Khalifa City, Abu Dhabi, United Arab Emirates.
Int J Infect Dis. 2022 Apr;117:334-344. doi: 10.1016/j.ijid.2022.02.019. Epub 2022 Feb 12.
Low ADAMTS13 activity has been suggested to be an interplaying factor in the pathogenesis of COVID-19, considering that it is a thromboinflammatory disease with high risk of microthrombosis.
The study aimed to explore the correlation between ADAMTS13 activity and the pathophysiological pathway of COVID-19.
We carried out a retrospective observational study of 87 patients with COVID-19 in NMC Royal Hospital, Abu Dhabi, UAE. ADAMTS13 activity was measured and compared with patients' characteristics and clinical outcomes.
Low ADAMTS13 activity was associated with pneumonia (p = 0.007), severity of COVID-19 (p <0.001), and mechanical ventilation rates (p = 0.018). Death was more frequently observed among patients (5 patients) with low ADAMTS13 activity compared with normal activity (1 patient), as well as inflammatory markers. Decreased ADAMTS13 activity increased with the risk of pneumonia, severity of COVID-19, need for mechanical ventilation, and use of anticoagulants ([OR = 4.75, 95% CI 1.54-18.02, p = 0.011], [OR = 6.50, 95% CI 2.57-17.74; p <0.001], [OR = 4.10, 95% CI 1.29-15.82; p = 0.024], [OR = 8.00, 95% CI 3.13-22.16; p <0.001], respectively). The low ADAMTS13 activity group had a slightly longer time to viral clearance than the normal ADAMTS13 activity group, but it was not statistically significant (20 days, 95% CI 16-27 days vs 17 days, 95% CI 13-22 days; p = 0.08; Log rank = 3.1).
Low ADAMTS13 activity has been linked to pneumonia, COVID-19 severity, use of anticoagulants, and need for mechanical ventilation but not to mortality. We propose rADAMTS13 as a novel treatment for severe COVID-19.
考虑到 COVID-19 是一种伴有高微血栓形成风险的血栓性炎症疾病,低 ADAMTS13 活性被认为是其发病机制中的一个相互作用因素。
本研究旨在探讨 ADAMTS13 活性与 COVID-19 病理生理途径之间的相关性。
我们对阿联酋阿布扎比 NMC 皇家医院的 87 例 COVID-19 患者进行了回顾性观察性研究。测量 ADAMTS13 活性,并将其与患者特征和临床结局进行比较。
低 ADAMTS13 活性与肺炎(p=0.007)、COVID-19 严重程度(p<0.001)和机械通气率(p=0.018)相关。与正常活性相比,低 ADAMTS13 活性患者(5 例)的死亡率更高(1 例),且炎症标志物也更高。随着肺炎、COVID-19 严重程度、机械通气需要和抗凝剂使用风险的增加,ADAMTS13 活性降低(OR=4.75,95%CI 1.54-18.02,p=0.011),(OR=6.50,95%CI 2.57-17.74;p<0.001),(OR=4.10,95%CI 1.29-15.82;p=0.024),(OR=8.00,95%CI 3.13-22.16;p<0.001)。低 ADAMTS13 活性组的病毒清除时间略长于正常 ADAMTS13 活性组,但无统计学意义(20 天,95%CI 16-27 天比 17 天,95%CI 13-22 天;p=0.08;Log rank=3.1)。
低 ADAMTS13 活性与肺炎、COVID-19 严重程度、抗凝剂使用和机械通气需要有关,但与死亡率无关。我们提出 rADAMTS13 作为治疗严重 COVID-19 的一种新方法。